Fibrin matrix containing high-dose calcitriol promotes the apoptosis of gastric cancer cells by sustainably releasing calcitrol and D-dimer
Source abstract
Abstract
The dose of 1,25-dihydroxyvitamin D 3 (calcitriol or VD), a promising therapeutic agent for gastric cancer, is limited by hypercalcemia if administered systemically. Here we explored the feasibility of applying fibrin matrix as high-dose VD carrier for topical application. Our results indicated that VD did not significantly alter the morphological, rheological and degradation characteristics of fibrin matrix except decreasing gelation time by its solvent DMSO. Furthermore, VD could be sustainably released from fibrin for more than 96 hours. Most importantly, fibrin containing high-dose VD increased gastric cancer cells apoptosis in contrast to VD alone of the same concentration, which might be due to the synergistic effects of sustained release of VD and D-dimer, the degradation products of fibrin. This study suggests that local delivery of high-dose calcitriol carried by fibrin matrix might be a promising adjuvant therapy for gastric cancer surgery.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Signaling Pathways in Disease · Pancreatic function and diabetes · Vitamin D Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pathology, Zhenjiang Hospital of Chinese Traditional and Western Medicine, Affiliated to Jiangsu University, Zhenjiang, China
Department of Oncology, Zhenjiang Hospital of Chinese Traditional and Western Medicine, Affiliated to Jiangsu University, Zhenjiang, China
Intensive Care Unit, Jiangyin People's Hospital, Jiangyin, China
Department of Pathology, Zhenjiang People's Hospital, Zhenjiang, China
School of Medicine, Jiangsu University, Zhenjiang, China
Funding
National Natural Science Foundation of China
References (44)
Show source-provided references
1. 10.1158/1055-9965.EPI-15-057810.1158/1055-9965.EPI-15-0578 ↗
2. 10.1016/S1470-2045(18)30132-310.1016/S1470-2045(18)30132-3 ↗
3. Bersanelli M · Future Med · 2017 · 2017 · 1127
4. 10.1016/j.jsbmb.2017.07.01010.1016/j.jsbmb.2017.07.010 ↗
5. 10.1056/NEJMoa180994410.1056/NEJMoa1809944 ↗
6. 10.3109/07435800.2015.103704810.3109/07435800.2015.1037048 ↗
7. 10.1158/1535-7163.MCT-15-006610.1158/1535-7163.MCT-15-0066 ↗
8. 10.1016/j.jsbmb.2018.07.00210.1016/j.jsbmb.2018.07.002 ↗
9. 10.1016/j.ygyno.2016.04.02210.1016/j.ygyno.2016.04.022 ↗
10. 10.1016/j.lfs.2017.04.02110.1016/j.lfs.2017.04.021 ↗
11. 10.1515/jbcpp-2017-012110.1515/jbcpp-2017-0121 ↗
12. 10.1111/cas.1330410.1111/cas.13304 ↗
13. 10.1016/j.steroids.2018.11.01410.1016/j.steroids.2018.11.014 ↗
14. 10.1016/j.ijpharm.2018.08.02210.1016/j.ijpharm.2018.08.022 ↗
15. Chen Q · Mol Cells · 2015 · 38 · 22110.14348/molcells.2015.2170 ↗
16. 10.1016/j.biomaterials.2015.01.05710.1016/j.biomaterials.2015.01.057 ↗
17. 10.1016/j.pharep.2018.02.01410.1016/j.pharep.2018.02.014 ↗
18. 10.1089/ten.teb.2008.052710.1089/ten.teb.2008.0527 ↗
19. Tredwell S · Can J Surg · 2006 · 49 · 347
20. 10.1111/cas.1239710.1111/cas.12397 ↗
21. 10.1002/bit.2559810.1002/bit.25598 ↗
22. 10.1016/j.biomaterials.2006.08.02710.1016/j.biomaterials.2006.08.027 ↗
23. 10.1007/s10856-011-4304-910.1007/s10856-011-4304-9 ↗
24. 10.1111/trf.1251110.1111/trf.12511 ↗
25. 10.1016/j.jconrel.2010.06.02510.1016/j.jconrel.2010.06.025 ↗
26. 10.1080/01635581.2013.81127310.1080/01635581.2013.811273 ↗
27. Chang S · Oncotarget · 2015 · 6 · 767510.18632/oncotarget.3048 ↗
28. Segovia-Mendoza M · Am J Cancer Res · 2017 · 7 · 1486
29. 10.1016/j.jsbmb.2015.12.00210.1016/j.jsbmb.2015.12.002 ↗
30. 10.1210/endo.141.1.728910.1210/endo.141.1.7289 ↗
31. 10.1126/science.275.5303.112910.1126/science.275.5303.1129 ↗
32. 10.1007/s40618-015-0381-910.1007/s40618-015-0381-9 ↗
33. 10.1089/ars.2014.588710.1089/ars.2014.5887 ↗
34. 10.1002/mnfr.20130050310.1002/mnfr.201300503 ↗
35. Mathiasen IS · Cancer Res · 1999 · 59 · 4848
36. 10.1074/jbc.M00687620010.1074/jbc.M006876200 ↗
37. 10.1016/j.jsbmb.2014.11.02210.1016/j.jsbmb.2014.11.022 ↗
38. 10.1089/dna.2017.405810.1089/dna.2017.4058 ↗
39. 10.1016/j.healun.2014.10.00810.1016/j.healun.2014.10.008 ↗
40. 10.1016/S1590-8658(01)80105-510.1016/S1590-8658(01)80105-5 ↗
41. 10.1186/s12885-016-3043-110.1186/s12885-016-3043-1 ↗
42. 10.1371/journal.pone.009054710.1371/journal.pone.0090547 ↗
43. 10.1007/s10147-018-1271-x10.1007/s10147-018-1271-x ↗
44. 10.1021/bi991096g10.1021/bi991096g ↗